Target Uric Acid Below 6 mg/dL

Target Uric Acid Below 6 mg/dL

This is my review of a uric acid treatment study. In which I will explain the key points for gout patients. So this is for people who are concerned about uric acid management. Because it explains the importance of patient education. In the hope that you can support your doctor’s treatment plan to achieve safe uric acid targets.

Citation for Target Uric Acid Below 6 mg/dL

This is a GoutPal review of:
Ruoff, Gary, and N. Lawrence Edwards. “Overview of serum uric acid treatment targets in gout: why less than 6 mg/dL?.” Postgraduate medicine 128, no. 7 (2016): 706-715.

At the time of writing, this study has been cited by 24 other studies.

Target Uric Acid Below 6 mg/dL Purpose

The purpose of this study is to explain why uric acid in gout patients needs to be reduced below 6 mg/dL. Rather than the common target of “normal”:

[uric acid in the blood] level in what an individual laboratory considers the ‘normal range’ may still reflect levels in joint tissues that are above the point for MSU crystal formation

Jargon-free Abstract

In the jargon-free abstract I present the key points of the original abstract. Replacing jargon with terms more familiar to unqualified people interested in gout. Note that my selection of jargon terms might not match yours. So please ask in the feedback form near the end of the page if you need clarification.

Background / Introduction
Gout is progressive. So without adequate uric acid control it leads to lumps of uric acid crystals and damage to joint structures.
Methods
The authors searched for studies concerning many aspects of gout management. Including some recommended guidelines. Then they reviewed the outcomes.
Results / Findings
Treating to a target below 6 mg/dL is effective. But doctors must adhere to treatment guidelines. Also, patient education is important to improve compliance.

Original Abstract

Gout is a progressive, painful, debilitating form of inflammatory arthritis. It is caused by factors that elevate the concentration of serum uric acid (sUA), leading to hyperuricemia (sUA >6.8 mg/dL). Continued elevated sUA can result in monosodium urate (MSU) crystal deposition in joints and soft tissues, and can cause acute and chronic inflammation. The prevalence of hyperuricemia and gout has increased over the last few decades, likely due to an aging population, changes in lifestyles and diet, and an increase in gout-associated comorbidities. Untreated or improperly treated gout can lead to chronic manifestation of the disease, including persistent inflammation, increased number of flares, development of tophi, and structural joint damage. Data show that even when patients are asymptomatic, ongoing inflammation and subsequent damage occurs locally at the joint and systemically. The aim of long-term treatment of gout is to reduce sUA levels to <6 mg/dL, which is below the saturation point of MSU (6.8 mg/dL), to inhibit formation of new crystals and to promote dissolution of existing crystals. Gout treatment should improve disease outcomes by eliminating gout flares, inducing long-term resolution of tophi, and more effectively managing comorbidities, many of which are associated with hyperuricemia. A number of studies have demonstrated that treating to the target of <6 mg/dL, by using effective therapies to lower sUA, results in reduction in the incidence of gout flares as well as shrinkage and eventual disappearance of tophi. Gout is often poorly managed due to a number of factors including lack of physician and patient adherence to treatment guidelines. Patients need to be educated about their diagnosis and management of the disease, such as the influence of diet and the importance of compliance with long-term treatment. With treatment, regular sUA monitoring, and patient adherence, gout is a curable disease.

Target Uric Acid Below 6 mg/dL Conclusions

For gout recovery, uric acid must be reduced below 6 mg/dL.

British Society of Rheumatology recommends the lower (<5 mg/dL) sUA target for all patients with gout. The idea behind treating to a target of <6 mg/dL and achieving lifelong maintenance of this level is to lower the concentration of sUA well below its saturation point and to provide some margin to accommodate the influence of natural fluctuations in uric acid levels. Lower sUA levels also increase the resolution rate of tophaceous deposits.

Uric Acid Crystals Dissolve Faster Below 6 mg/dL
Uric Acid Crystals Dissolve Faster Below 6 mg/dL

Cited By

Normal Uric Acid Confusion
When is uric acid safe? Confusion comes from the normal uric acid range. Because it’s normal for some people to have gout. See if you are safely below 6 mg/dL.

For email notifications when I publish more study reviews here, please subscribe to this website:

Enter your email address:

No Charge.
Subscription is free.
100% Safety Guaranteed.
Your email address is safe - I will never share it with anyone else.
No Commitment.
Each of my update emails ends with an Unsubscribe link. So, you can stop updates whenever you like. Then, rejoin whenever you like. You are in control.

Leave Target Uric Acid Below 6 mg/dL to read Gout Library Home Page.



Target Uric Acid Below 6 mg/dL Vocabulary

  • hyperuricemia

    ⇢ high uric acid

  • MSU (MonoSodium Urate)

    ⇢ uric acid (usually crystals) bonded with sodium and water molecules.

  • sUA (serum Uric Acid)

    ⇢ uric acid in the blood

  • tophaceous

    ⇢ having, or related to lumps of uric acid crystals (see tophus)

  • tophus (plural = tophi)

    ⇢ lump of uric acid crystals

Common Terms: , , ,

Other posts that include these terms: